Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pharvaris N.V. - Ordinary Shares (NQ:PHVS)

24.41 +0.39 (+1.62%)
Streaming Delayed Price Updated: 9:38 AM EST, Dec 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Pharvaris N.V. - Ordinary Shares

< Previous 1 2 3 4 Next >
News headline image
This Biotech Fund Just Made a $22 Million Bet on Pharvaris Stock — Is It a Buy? ↗
A late-stage biotech with three pivotal trials underway just landed a major hedge-fund backer — here’s why the timing matters. 
Via The Motley Fool
News headline image
Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares ↗
Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
PHVS Stock Jumps After Phase 3 Trial Shows Rapid Symptom Relief For Oral HAE Treatment ↗
The RAPIDe-3 Phase 3 study is Pharvaris’ first trial for on-demand treatment of HAE attacks. 
Via Stocktwits
News headline image
A $68 Million Signal: What General Atlantic Sees in Pharvaris Right Now ↗
General Atlantic is building its position just as Pharvaris nears pivotal readouts. This article breaks down what the fund may be anticipating and the signals investors should track next. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Analyst Expectations for Pharvaris's Future ↗
 
Via Benzinga
News headline image
What One Fund's Sale of Centessa Stock Signals About the Fast-Rising Biotech Company ↗
Here's why a fast-rising pharmaceutical trimmed—and not abandoned—by a specialist fund signals ongoing conviction in the stock. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Investment Powerhouse Backs Biotech Stock to the Tune of $419 Million ↗
Bain Capital added more than 12.4 million shares of HeartFlow stock in the thrid quarter 
Via The Motley Fool
Topics Artificial Intelligence Regulatory Compliance
News headline image
Institutional Titan Hits the Jackpot: Biotech Stock Surges by 116% on Buyout Offer ↗
Bain Capital's bet on Cidara Therapeutics stocks has paid off in a big way 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech Stock Gets Booted in Latest Fund Update ↗
Bain Capital sold its entire stake in Nuvalent stock during the third quarter. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Portfolio Adjustment: Institutional Heavyweight Exits Biotech Stock ↗
Bain Capital completely exited its position in Disc Medicine stock during the third quarter 
Via The Motley Fool
News headline image
5AM Venture Just Dumped Its Viking Stake—Smart Call or Missed Opportunity? ↗
One major biotech investor just walked away from Viking Therapeutics. Here’s what the move may—and may not—mean for the company’s clinical-stage future. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
5AM Venture Bails on MoonLake After a Brutal Year: Here’s What Stands Out ↗
A major biotech investor just walked away from MoonLake after a rough year for the stock. Here’s what that move signals—and what long-term investors should keep an eye on next. 
Via The Motley Fool
News headline image
Why Bain Capital Is Selling Shares of This Biotech Stock Now ↗
Bain Capital sold $20 million worth of Pharvaris stock during the third quarter. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Uber Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗
 
Via Benzinga
News headline image
Pharvaris NV (NASDAQ:PHVS) Reports Wider Q2 2025 Loss, Highlights Clinical Trial Progress ↗
Pharvaris NV (PHVS) reported a Q2 2025 loss of €0.83/share, missing estimates. Revenue was nil as R&D spend rose. Focus remains on Phase 3 trials for deucrictibant in HAE/AAE-C1INH, with key data... 
Via Chartmill
News headline image
PHVS Stock Earnings: Pharvaris Beats EPS for Q2 2024 ↗
PHVS stock results show that Pharvaris beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
Biogen Has Up To $10 Billion For Acquisitions; Why These Three Names Make Sense ↗
Biogen has $8 billion to $10 billion in dry powder for acquisitions. Here are three names the company could examine. 
Via Investor's Business Daily
News headline image
PHVS Stock Earnings: Pharvaris Misses EPS for Q1 2024 ↗
PHVS stock results show that Pharvaris missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
PHVS Stock Earnings: Pharvaris Misses EPS for Q4 2023 ↗
PHVS stock results show that Pharvaris missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Top-Notch Pharvaris Eyes Profit-Taking Zone On A Key FDA Decision ↗
The company is working on a treatment for swelling attacks associated with a genetic disease. 
Via Investor's Business Daily
News headline image
FDA Clears Pharvaris' Trial For Investigational Drug For Swollen Blood Vessels, Stock Jumps ↗
Pharvaris receives FDA approval to advance deucrictibant for hereditary angioedema prophylaxis, lifting clinical hold. Learn about the latest developments in HAE treatment. 
Via Benzinga
News headline image
Gold Moves Higher; Campbell Soup Earnings Top Expectations ↗
U.S. stocks traded mixed toward the end of trading on Wednesday. The Dow traded up 0.05% to 36,143.40 while the NASDAQ fell 0.06% to 14,221.51. The S&P 500 also fell, dropping, 0.05% to 4,564.73. 
Via Benzinga
Topics Stocks
News headline image
Why AeroVironment Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
Shares of AeroVironment, Inc. (NASDAQ: AVAV) moved lower during Wednesday’s session following second-quarter results. 
Via Benzinga
News headline image
Turnaround For Pharvaris Since FDA Clinical Hold - Data Shows Its Oral Hereditary Angioedema Treatment Cuts Attacks ↗
Pharvaris NV (NASDAQ: PHVS) released topline data from the CHAPTER-1 Phase 2 study meeting its primary endpoint, with deucrictibant demonstrating statistically significant and clinically meaningful... 
Via Benzinga
News headline image
Crude Oil Down 4%; Pharvaris Shares Spike Higher ↗
U.S. stocks traded mostly flat midway through trading, with the S&P 500 turning lower on Wednesday. The Dow traded up 0.01% to 36,126.75 while the NASDAQ rose 0.03% to 14,233.77. The S&P 500 also fell,... 
Via Benzinga
Topics Stocks
News headline image
AMD Stock Alert: What to Expect From Advanced Micro Devices ‘Advancing AI’ Event ↗
Advanced Micro Devices stock is climbing higher on Wednesday as AMD investors prepare for the company's Advancing AI event today. 
Via InvestorPlace
Topics Artificial Intelligence
News headline image
THOR Industries Reports Upbeat Earnings, Joins Dave & Buster's Entertainment, Campbell Soup And Other Big Stocks Moving Higher On Wednesday ↗
U.S. stocks traded higher, with the Dow Jones index gaining more than 50 points on Wednesday. 
Via Benzinga
Topics Stocks
News headline image
Shopify (SHOP) Stock Falls Following Analyst Downgrade ↗
Shopify stock is taking a beating on Wednesday after shares of SHOP were hit with a downgrade from Wedbush analyst Scott Devitt. 
Via InvestorPlace
News headline image
Why Is Pharvaris (PHVS) Stock Up 36% Today? ↗
Pharvaris stock is rising higher on Wednesday following news of an underwritten offering for PHVS shares and pre-funded warrants. 
Via InvestorPlace
News headline image
US Stocks Higher; Private Payrolls Rise By 103,000 In November ↗
U.S. stocks traded higher this morning, following the release of economic reports on Wednesday. Following the market opening Wednesday, the Dow traded up 0.21% to 36,200.86 while the NASDAQ rose 0.28%... 
Via Benzinga
Topics Stocks
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.